Literature DB >> 16283436

Intracavitary chemotherapy (Gliadel) for recurrent esthesioneuroblastoma: case report and review of the literature.

Michael C Park1, Charles E Weaver, John E Donahue, Prakash Sampath.   

Abstract

Esthesioneuroblastoma is an uncommon malignancy of the nasal vault with a treatment regimen consisting of surgical resection followed by radiotherapy for primary lesions and addition of chemotherapy for patients with advanced, recurrent or metastatic lesions. We report a case of a 39-year-old female with a history of esthesioneuroblastoma, previously treated with resection, radiation and chemotherapy, presenting with a recurrent disease that was successfully treated with re-resection and placement of Gliadel) wafers in the surgical resection cavity. The novel option of controlled-release and local delivery of a chemotherapeutic agent for treatment of recurrent esthesioneuroblastoma should be recognized and considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16283436     DOI: 10.1007/s11060-005-7411-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

Review 1.  Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924.

Authors:  G Broich; A Pagliari; F Ottaviani
Journal:  Anticancer Res       Date:  1997 Jul-Aug       Impact factor: 2.480

Review 2.  Esthesioneuroblastoma: a meta-analysis and review.

Authors:  P Dulguerov; A S Allal; T C Calcaterra
Journal:  Lancet Oncol       Date:  2001-11       Impact factor: 41.316

3.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Authors:  Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

4.  Esthesioneuroblastoma. Long-term outcome and patterns of failure--the University of Virginia experience.

Authors:  B V Eden; R F Debo; J M Larner; M D Kelly; P A Levine; F M Stewart; R W Cantrell; W C Constable
Journal:  Cancer       Date:  1994-05-15       Impact factor: 6.860

5.  Esthesioneuroblastoma: reflections of a 21-year experience.

Authors:  P A Levine; R Gallagher; R W Cantrell
Journal:  Laryngoscope       Date:  1999-10       Impact factor: 3.325

6.  Implantable Slow-Release Chemotherapeutic Polymers for the Treatment of Malignant Brain Tumors.

Authors: 
Journal:  Cancer Control       Date:  1998-03       Impact factor: 3.302

7.  Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.

Authors:  Dong-Wan Kim; Yo-Han Jo; Jee Hyun Kim; Hong-Gyun Wu; Chae Seo Rhee; Chol Hee Lee; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang; Noe Kyeong Kim
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

8.  Esthesioneuroblastoma: prognosis and management.

Authors:  A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

9.  Treatment of recurrent esthesioneuroblastoma with combined intra-arterial chemotherapy. A case report.

Authors:  K Watne; B Hager
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

10.  Gliadel for pituitary adenomas and craniopharyngiomas.

Authors:  Edward R Laws; Angel M Morris; Nicholas Maartens
Journal:  Neurosurgery       Date:  2003-08       Impact factor: 4.654

View more
  2 in total

1.  Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database.

Authors:  Mary E Platek; Mihai Merzianu; Terry L Mashtare; Saurin R Popat; Nestor R Rigual; Graham W Warren; Anurag K Singh
Journal:  Radiat Oncol       Date:  2011-04-25       Impact factor: 3.481

2.  Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Authors:  Daniela A Bota; Annick Desjardins; Jennifer A Quinn; Mary L Affronti; Henry S Friedman
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.